About ATAI
ATAI is a Healthcare company based in Munchen (Germany) founded in 2018. A biopharmaceutical company accelerating innovative mental health treatments. It operates on a B2B model. ATAI has raised $386.67 million across 6 funding rounds from investors including Galaxy, George Goldsmith and Apeiron Investment Group. ATAI has completed 2 acquisitions, including Kures and Psyber. ATAI was last valued at $2 billion in March 2021. Its website atai.life draws about 681 thousand monthly visits. Its focus areas include Biopharmaceuticals, Mental Health and Treatment Development.
Company details
ATAI a biopharmaceutical company accelerating innovative mental health treatments through providing healthcare solutions, biopharmaceuticals, supporting mental health solutions, and treatment development. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Funding Insights of ATAI
ATAI has successfully raised a total of $386.67M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $157 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $386.67M
- Total Rounds 6
- Last Round Series D — $157M
- First Round $12.6M
(Jun 2018)
- Investors Count 25
All 6 funding rounds of ATAI with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $157M | Series D | $2B | Apeiron Investment Group, Thiel Capital | |
| Nov 2020 | $125M | Series C | – | Apeiron Investment Group | |
| Apr 2020 | $24M | Series B | – | Steve Jurvetson, Peter Thiel | – |
| May 2019 | $43M | Series B | – | Subversive Capital | |
| Oct 2018 | $25.07M | Series A | – | QC·VENTURES | |
| Jun 2018 | $12.6M | Seed | – | Apeiron Investment Group, George Goldsmith |
| Date | Valuation | Stage |
|---|---|---|
| Mar 2021 | $2B | •••••••• |
Last known valuation $2B (Mar 2021). 25 investors in total: 14 institutional and 11 angel.
Investors in ATAI
ATAI has secured backing from 25 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Galaxy, George Goldsmith and Apeiron Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm backed by Christian Angermayer | apeiron-investments.com | Sliema, Malta | ||
Thiel Capital is involved in investment and financial activities. | thielcapital.com | |||
VC firm making sector agnostic investments | fearless.vc | San Francisco, United States | ||
Venture capital is provided to biomedical technology startups. | cataliocapital.com | New York, United States | ||
Venture capital firm focused on growth-stage companies | alphawaveglobal.com | New York, United States | ||
Future Ventures is focused on early-stage venture capital investments. | future.ventures | Los Altos, United States | ||
Investment management services are provided focusing on healthcare innovation. | puravidainvestments.com | New York, United States | ||
Venture capital investments are provided by QC Ventures. | qc-ventures.com | Vienna, Austria | ||
An equity-strategy focused hedge fund for investment management. | 2018 | woodlinepartners.com | San Francisco, United States | |
Subversive Capital is focused on investing in disruptive ideas. | subversivecapital.com | New York, United States |
Investor details for ATAI
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ATAI
12 people are tracked at ATAI (3 in leadership, 2 in board & advisors, 7 in team).
| Name | Role | Group |
|---|---|---|
Christian Angermayer | Founder | Leadership |
Donna Cabral-Lilly | Vp, CMC | Leadership |
Cara Philippou Baugh | Senior Director, Associate General Counsel | Leadership |
Heslin Smiley | Supervisory Board Member | Board & advisors |
Sabrina Martucci | Supervisory Board Member | Board & advisors |
Arvind Tewari | Lead, Digital Strategy & Operations | Team |
Majed Fawaz | Lead, Chemistry, Manufacturing & Controls | Team |
Greg Bates | Lead, Regulatory Affairs | Team |
Ryan Barrett | Lead, Corporate Development & General Counsel | Team |
Anne Johnson | Lead, Global Controller | Team |
Roman Dahl | Lead, Innovation Strategy & Operations | Team |
Gaurav Kumar Ganotra | Associate, Business Intelligence | Team |
Complete people profiles for ATAI
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ATAI
ATAI has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Kures and Psyber.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Website development and digital marketing services are provided by Psyber. | psyber.co | Mumbai, India | 2014 | Apr 2021 | •••• | |
Opioid-based therapeutics for mood and depression disorders are developed. | kuresinc.com | New York, United States | 2015 | Jul 2020 | •••• |
Complete acquisition details for ATAI
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of ATAI
6 dated milestones of ATAI across 3 years, from founding to its latest funding, stage changes and deals.
Web traffic of ATAI
The website of ATAI (atai.life) receives about 680.7K visits a month and ranks #4,205,900 among all websites worldwide, #3,905 in Addictions.
- Monthly visits680.7K
▼ 6.7% vs previous month
- Unique visitors1.7K
per month
- Global rank#4,205,900
among all websites
- Category rank#3,905
Health · Addictions
- Bounce rate40%
- Pages per visit1.7
- Average visit39 sec
- DevicesDesktop 27% · Mobile 73%
Websites whose visitors overlap most with ATAI. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| falconebiz.com | 100% | 959.8K | #63,970 | View details | |
| tofler.in | 97% | 556K | #105,509 | View details | |
| zaubacorp.com | 96% | 4.9M | #12,689 | View details | |
| tracxn.com | 92% | 2.9M | #16,597 | View details | |
| indiafilings.com | 90% | 2.1M | #29,959 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for ATAI
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Atai
Complete news archive for ATAI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ATAI
ATAI was founded in 2018.
ATAI is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
ATAI is a funded company, having raised a total of $386.67M across 6 funding rounds to date. The company's 1st funding round was a Seed of $12.6M, raised on Jun 2018.
ATAI a biopharmaceutical company accelerating innovative mental health treatments through providing healthcare solutions, biopharmaceuticals, supporting mental health solutions, and treatment development. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
ATAI has 25 investors. Key investors include Galaxy, George Goldsmith, Apeiron Investment Group, Thiel Capital, and Woodline Partners.
The valuation of ATAI is $2B as of Mar 2021.
The website of ATAI receives about 681 thousand visits a month and ranks #4,205,900 among all websites worldwide.